Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama 700-8558, Japan.
Department of Internal Medicine, Tsuyama Chuo Hospital, Tsuyama 7080841, Japan.
World J Gastroenterol. 2017 Sep 7;23(33):6155-6163. doi: 10.3748/wjg.v23.i33.6155.
To identify the clinical features of gastric mucosa-associated lymphoid tissue (MALT) lymphoma with extra copies of MALT1.
This is a multi-centered, retrospective study. We reviewed 146 patients with MALT lymphoma in the stomach who underwent fluorescence in situ hybridization analysis for t(11;18) translocation. Patients were subdivided into patients without t(11;18) translocation or extra copies of MALT1 (Group A, n = 88), patients with t(11;18) translocation (Group B, n = 27), and patients with extra copies of MALT1 (Group C, n = 31). The clinical background, treatment, and outcomes of each group were investigated.
Groups A and C showed slight female predominance, whereas Group B showed slight male predominance. Mean ages and clinical stages at lymphoma diagnosis were not different between groups. Complete response was obtained in 61 patients in Group A (69.3%), 22 in Group B (81.5%), and 21 in Group C (67.7%). Helicobacter pylori (H. pylori) eradication alone resulted in complete remission in 44 patients in Group A and 13 in Group C. In Group B, 14 patients underwent radiotherapy alone, which resulted in lymphoma disappearance. Although the difference was not statistically significant, event-free survival in Group C tended to be inferior to that in Group A (P = 0.10).
Patients with t(11;18) translocation should be treated differently from others. Patients with extra copies of MALT1 could be initially treated with H. pylori eradication, similar to patients without t(11;18) translocation or extra copies of MALT1.
鉴定伴有额外 MALT1 拷贝的胃黏膜相关淋巴组织（MALT）淋巴瘤的临床特征。
这是一项多中心、回顾性研究。我们对 146 例接受荧光原位杂交分析 t（11；18）易位的胃 MALT 淋巴瘤患者进行了研究。患者被分为无 t（11；18）易位或额外 MALT1 拷贝（A 组，n=88）、t（11；18）易位患者（B 组，n=27）和额外 MALT1 拷贝患者（C 组，n=31）。对每组患者的临床背景、治疗和结局进行了调查。
A 组和 C 组显示出轻微的女性优势，而 B 组则显示出轻微的男性优势。各组间淋巴瘤诊断时的平均年龄和临床分期无差异。A 组 61 例（69.3%）、B 组 22 例（81.5%）和 C 组 21 例（67.7%）获得完全缓解。A 组 44 例和 C 组 13 例单独行幽门螺杆菌（H. pylori）根除治疗后完全缓解。B 组 14 例单独行放疗，结果淋巴瘤消失。尽管差异无统计学意义，但 C 组的无事件生存时间似乎劣于 A 组（P=0.10）。
伴有 t（11；18）易位的患者应与其他患者区别对待。伴有额外 MALT1 拷贝的患者可与无 t（11；18）易位或额外 MALT1 拷贝的患者一样，最初行 H. pylori 根除治疗。
